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Abstract
Objective—Genetic variation in matrix metalloproteinase (MMP) promoter regions alters the
transcriptional activity of MMPs and has been consistently associated with CHD, presumably through
plaque degradation and remodeling. We examined the association of MMP promoter variation with
multiple plaque characteristics measured by gadolinium-enhanced MRI among 1,700 participants in
the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study.
Methods—For the analyses presented here, 1,700 participants of the biracial ARIC Carotid MRI
Study (~1,000 participants with thick carotid artery walls and ~700 randomly sampled participants)
were evaluated for associations of MMP genetic variation with multiple plaque characteristics,
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including carotid artery wall thickness, lipid core and fibrous cap measures. MRI studies were
performed on a 1.5T scanner equipped with a bilateral 4-element phased array carotid coil.
Results—Fifty-one percent of the participants were female, 77% white, 23% African American,
and the mean age was 70 years. MMP2 C-1306T variant genotypes (CT+TT) were significantly
associated with higher cap thickness measures, but not with wall thickness or lipid core measures.
Individuals with the CC genotype had approximately 0.1 mm thinner cap thickness compared to
those carrying a T allele (p=0.02).
Conclusion—Genetic variation within the MMP2 promoter region was associated with cap
thickness and therefore may influence the role of MMP2 in plaque vulnerability.
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Introduction
Matrix metalloproteinases (MMPs) are a family of enzymes present and enzymatically active
in atherosclerotic plaques (1-3). MMP expression is primarily regulated at the transcription
level, with single nucleotide polymorphisms (SNPs) in the promoter regions of MMPs shown
to alter transcriptional activity and contribute to cardiovascular disease susceptibility (1,4-6).
MMPs can degrade a range of extracellular matrix proteins and are implicated in connective
tissue degradation and remodeling associated with the development of atherosclerotic lesions.
Both observational and functional studies have investigated the role of MMP genetic variation
with regards to gene expression, disease susceptibility and vascular remodeling (1,5-8). Studies
indicate that MMP genetic variation may contribute to individual differences in complex
disease susceptibility through effects on the balance between the synthesis and degradation of
extracellular matrix proteins (1,5-8). In previous studies, MMP2, MMP3 and MMP12 gene
promoter variations have been associated with coronary heart disease (CHD) (2,6-18). The
mechanism of the association between MMP gene variation and CHD is presumed to be the
result of the effects of the MMP activity on fibrous cap thickness and the genesis of vulnerable
plaques (18).
In this study, we used gadolinium-enhanced carotid MRI to measure atherosclerotic plaque
characteristics among 1,700 participants in the Atherosclerosis Risk in Communities (ARIC)
study and to examine the association between targeted MMP gene variation and plaque
characteristics, with specific a priori hypotheses related to fibrous cap thickness. The genes
and SNPs that were selected were those that have previously been associated with CHD in
multiple population-based or case-control studies.
Methods
Study Design and Study Participants
The ARIC Carotid MRI Study was conducted between 2004 and 2005. The participants were
selected from the ARIC study cohort based on results of the last ultrasound examinations (Visits
3 and 4, 1993-1998). The ARIC study is a prospective investigation of atherosclerosis and its
clinical sequelae involving 15,792 African American and white men and women aged 45 to
64 years at recruitment (1987-1989). Participants underwent a baseline and up to three follow-
up visits through 1998. A detailed description of the ARIC study design and methods has been
published elsewhere (19). Two groups were recruited for the ARIC Carotid MRI Study: ~1,200
participants with thick carotid artery walls based on ultrasound exams from visits 3 and 4
(>85th percentile intima-media thickness (IMT); “high IMT group”) and ~800 participants
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randomly sampled from the remainder of the cohort (<85th percentile IMT; “not-high group”).
The carotid artery IMT cutpoint was determined for each field center based on the IMT
distribution specific to that site. The participants were screened for contraindications to MRI
or to contrast media. In addition, selected participants also received in-person interviews and
a physical examination. The study was approved by local Institutional Review Boards. For the
current analyses, participants were excluded if they prohibited use of their DNA for research
purposes or had missing information for all measurement variables. Following exclusions, a
total of 1,701 participants were available for analysis.
MRI Protocol
MRI studies were performed on a 1.5T scanner (GE Medical Systems, Milwaukee, WI at three
field centers; Siemens Medical Solutions, Ehrlangen, Germany at one field center) equipped
with a bilateral 4-element phased array carotid coil (Machnet, The Netherlands). A 3-
dimensional time-of-flight MR angiogram was acquired through the extracranial carotid
bifurcations and this was used to identify the carotid artery with the thicker wall or plaque.
Each participant received an intravenous injection of gadodiamide (Omniscan, GE
Amersham), 0.1 mmol/kg body weight, using a power injector. Sixteen axial T1-weighted, fat-
suppressed BBMRI slices (thickness, 2mm; acquired in-plane resolution, 0.51×0.58mm2; total
longitudinal coverage, 3.2cm) were oriented perpendicular to the vessel and centered at the
thickest part of the internal or common carotid artery wall. These 16 slices were acquired five
minutes after the intravenous injection of gadodiamide (Omniscan, GE Amersham), 0.1 mmol/
kg body weight, with a power injector.
Image Analysis
MRI images were analyzed by seven readers, blinded to the clinical and laboratory
characteristics of the study population, using semiautomated software (VesselMASS, The
Netherlands). All exams were assessed for image quality and protocol adherence, and exams
that failed were not analyzed. Slices were numbered 1 through 16 from proximal to distal and
only slices 4 through 11 were analyzed. If these 8 slices did not contain the thickest part of the
plaque, then the reader continued contouring in the direction of the thickest wall (i.e. slices 1
through 11 or slices 4 through 16).
The plaque components were analyzed on the postcontrast BBMRI series based on the ability
of gadolinium enhancement to delineate and enable quantitative size measurements of the
fibrous cap (20,21) and contours were drawn to delineate the lumen, lipid core, and outer wall.
The fibrous cap contour was automatically generated based on the lipid core and lumen
contours. Using semi-automated software, the vessel walls were divided into 12 radial
segments. Mean, minimum, and maximum thickness values were generated for each segment.
The fibrous cap was divided into radial segments at 15° increments, and mean, minimum, and
maximum thickness measurements were generated for each segment. Area measurements also
were generated for the lipid core contours. Volumetric data were computed by integrating area
measurements over all slices.
Examination and Laboratory Measures
All measures utilized in these analyses were from the 2004-2005 MRI exam. Seated blood
pressure was measured three times with a random-zero sphygmomanometer and the last two
measurements were averaged. Hypertension was defined as systolic blood pressure ≥ 140 mm
Hg or diastolic blood pressure ≥ 90 mm Hg or current use of antihypertensive medications.
Questionnaires and in-person interviews were used to assess use of antihypertensive
medications. Diabetes was defined by a fasting glucose level ≥ 126 mg/dL, a non-fasting
glucose level ≥ 200 mg/dL, and/or history of or treatment for diabetes. Cigarette-smoking status
was analyzed by comparing current smokers to individuals who had formerly or never smoked.
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Body mass index (BMI, kg/m2) was calculated from height and weight measurements. Plasma
total cholesterol was measured by an enzymatic method (22). High-density lipoprotein (HDL)
cholesterol was measured after dextran-magnesium precipitation of non-HDL lipoproteins
(23).
Genotype Determination
Known functional promoter or missense mutations in the matrix metalloproteinase (MMP)
gene family or SNPs previously reported to be associated with cardiovascular conditions were
selected for investigation. The polymorphisms included: MMP2 G-1575A (rs243866), MMP2
C-1306T (rs243865), MMP2 T-790G (rs243864), MMP3 5A/6A (rs35068180), MMP3 K45E
(rs679620), MMP7 A-181G (rs11568818), MMP7 C-153T (rs11568819), MMP9 R279Q
(rs17576), MMP12 A-82G (rs2276109) MMP13 A-77G (rs2252070). Genotyping was carried
out using the SNPlex or TaqMan Assays (Applied Biosystems, Inc, Foster City, CA). Primers
and probes are available from the authors upon request.
Statistical Analysis
All analyses were based on methods appropriate for a stratified random sample. In particular,
all analyses were weighted by the inverse of the sampling fractions in the eight sampling strata
(4 field centers × 2 IMT groups). The sampling fractions were based on those persons actually
screened for participation. Those who actually participated (non-refusing eligibles) were
analyzed as a sub-population in calculating variances and confidence intervals of estimators.
Analyses were conducted utilizing SAS version 9.1 for descriptive statistics (PROC
SURVEYMEANS, PROC SURVEYFREQ) and SUDAAN for linear and logistic regression.
Finite population correction factors were not applied. Tests of differences in weighted means
or proportions between groups were from weighted linear or logistic regression models that
accounted for the sampling. Adjusted means and proportions by sub-group of interest were
calculated using SUDAAN REGRESS for continuous variables and LOGISTIC for
dichotomous variables, with predicted values calculated as sample means of the adjusting
variables.
Genotype frequencies were calculated as weighted frequencies using SUDAAN CROSSTAB,
and allele frequencies were calculated from genotype frequencies as P(AA) + P(AB)/2, where
P(AA) and P(AB) are the weighted frequencies of AA and AB, respectively. The test for Hardy-
Weinberg equilibrium used the weighted genotype frequencies and their covariance matrix,
applying the delta method to obtain the test statistic. Variant alleles were identified as the low
frequency allele in whites, and homozygous wildtype (non-variant) genotypes were designated
as the referent group in the statistical analyses.
Results
Descriptive statistics of the ARIC Carotid MRI Study participants are presented in Table 1
stratified by race and gender. African Americans had higher mean LDL cholesterol and a higher
occurrence of diabetes and hypertension compared to whites. Whites had a higher percentage
of former smokers and statin users compared to African Americans. Carotid artery wall
thickness, lipid core and cap measures are presented in Table 2 stratified by race and gender.
Statistically significant race-gender differences were observed for all carotid artery wall
thickness and lipid core measures. Men, especially white men, had greater wall thickness than
the women. White men also had a larger percent of plaques with a lipid core and a greater lipid
core volume, when present, compared to the other groups. No significant race-gender
differences were observed for cap measures.
Volcik et al. Page 4
Atherosclerosis. Author manuscript; available in PMC 2011 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
All MMP genotype distributions were in accordance with Hardy-Weinberg equilibrium
expectations. Statistically significant associations were observed between the three MMP2
SNPs (rs243864, rs243865, rs243866) and all cap measures. No significant associations were
observed for the other MMP SNPs studied. The allele frequencies for each of the three MMP2
SNPs were similar within each racial group, but allele frequencies were disparate between
whites and African Americans. Allele frequencies for each MMP2 SNP were as follows for
whites and African Americans, respectively: rs243864 f(G)=0.23 and 0.06, rs243865 f(T)=0.23
and 0.07, rs243866 f(A)=0.23 and 0.06. Further examination of the linkage disequilibrium
(LD) pattern of the MMP2 gene showed these three SNPs to be in high LD with one another
(in a single LD block; r2=1.0 for all three SNPs). Therefore, we present here the results for the
single MMP2 SNP, rs243865, which was designated as the tagSNP for this MMP2 linkage
block. Results for the additional MMP2 SNPs investigated (rs243864 and rs243866) are
provided in supplemental tables available on-line.
Carotid artery wall thickness, lipid core and cap measures for the ARIC Carotid MRI
participants by MMP2 rs243865 genotype are presented in Table 3. MMP2 variant genotypes
were not significantly associated with measures of carotid artery wall thickness or lipid core
measures, but were consistently associated with significantly higher cap thickness measures.
This association was present and statistically significant over a wide variety of adjustments
that were explored (data not shown). Individuals with the CC genotype had approximately 0.1
mm thinner cap thickness compared to those carrying a T allele. This effect was also evident
when the analysis was restricted to the sample of white participants. The mean cap thickness
in whites with the CC genotype was 0.637 compared to 0.746 for those carrying a T allele
(p=0.02). There were insufficient numbers of African Americans with cap measurements to
support race-specific analyses in that group.
Discussion
An atheromatous plaque is a complex lesion composed of distinct morphological features,
including a fibrous cap, a shoulder area and a lipid core. Histological studies have demonstrated
that specific characteristics of the plaque structure influence the risk of plaque rupture (24). A
plaque with a thin fibrous cap and a large lipid core is more vulnerable to rupture, whereas a
plaque with a thick fibrous cap and a small lipid core is considered to be stable (25-27). It has
been postulated that thin cap fibroatheroma are the precursor lesion of plaque rupture (25). In
concurrence with histological evidence, noninvasive high-resolution MRI has shown a
significant association between the in vivo state of the fibrous cap and recent history of stroke
(28), as well as the importance of fibrous cap status in the development of future ischemic
complications (29). Since plaque rupture and formation may result in thrombosis and an acute
cardiovascular disease event, it is important to identify factors that modify the plaque structure,
especially those that lead to instability by causing the formation of a thin cap and large lipid
core.
The extracellular matrix (ECM) of the fibrous cap, comprised of multiple macromolecules
including collagen and smooth muscle cells, provides the structural integrity of a plaque and
contributes to plaque formation and progression (30). Although the mechanisms underlying
plaque rupture are incompletely known, MMPs play a central role in the degradation of ECM
components and therefore may contribute to the destabilization and thinning of the fibrous cap
and subsequent plaque rupture (5,8,30,31). MMP degradation of the ECM can be influenced
by a number of regulatory mechanisms, the most notable being transcriptional regulation (6).
MMP transcript levels have been shown to be higher in thin cap plaques compared to plaques
with a thick fibrous cap, as well as MMP transcript levels being increased in ruptured plaques
compared with lesions without cap disruption (32).
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Experimental studies have reported that MMP2 and MMP9, both gelatinase MMPs, are
overexpressed and enzymatically active within vulnerable sites of human atheroma (4,18,31,
33). MMP2 and MMP9 are considered to be involved in plaque stability/instability due to their
role in the cleaving of matrix proteins (e.g. type IV collagen) and non-matrix substrates (e.g.
CD-44, cadherins) which promote migration, proliferation and viability of vascular smooth
muscle cells, all of which are processes expected to favor plaque-cap stability (34-36). A recent
study by Kuge and colleagues showed MMP2 immunohistochemical staining to be
significantly and positively correlated with morphological vulnerability of atheromatous
lesions in hypercholesterolemic rabbits with pathological characteristics relevant to human
atherosclerosis (34). The findings from Kuge and colleagues, as well as previous studies,
support the hypothesis that MMP2 activity plays a pivotal role in the destabilization of
atherosclerotic plaques (4,18,31,33,34). Immunohistochemical staining for MMP2 has also
been observed to be more prevalent in plaques with expansive remodeling, which may
predispose to plaque rupture (37-40).
The MMP2 C-1306T variant is a functional SNP that abolishes a Sp1 binding site within the
promoter region of the MMP2 gene and thus results in lower promoter activity (11). Genotypes
carrying the variant −1306T allele have been shown to result in lower levels of MMP2 mRNA,
and therefore lower gene expression and lower MMP2 levels (41). These observations support
our hypothesis that persons carrying the variant −1306T allele have decreased MMP2
expression/levels and thus have thicker caps compared to persons with the −1306CC genotype.
Presence of the −1306T allele would thus favor plaque-cap stability. For the current study,
MMP2 levels were available on a subset of the population. The MMP2 C-1306T variant was
associated with MMP2 levels, with lower levels observed in persons carrying the −1306T
variant allele compared to persons with the −1306CC genotype (CC = 304.0 ± 1.1 ng/ml, CT
+TT = 301.1 ± 1.6 ng/ml, P=0.1).
We observed that compared to individuals carrying the T allele, individuals with the CC
genotype had approximately 0.1 mm thinner caps, a difference of approximately 15% of the
mean cap thickness. The lower mean cap thickness for those individuals with the CC genotype
(0.64 mm) will include a range of thicknesses that encompass more values below the
pathologically-determined threshold for rupture (165 microns) than those individuals carrying
the T allele (42). This suggests a higher susceptibility to rupture with thrombus formation for
those with the CC genotype, potentially putting these individuals at a higher risk for stroke.
Limitations to the current study include replication, the technology of the MRI and plaque
characterization, and correction for multiple testing. First of all, we were unable to replicate
our findings due the uniqueness of the MRI phenotypes characterized in the ARIC Carotid
MRI study. Second, the resolution constraints of the MRI scanner limited our ability to detect
features within the smallest plaques, so only the largest plaques found within the thickest
arterial walls were studied to limit the impact of these constraints. By truncating the distribution
of lipid core volume and cap thickness, we have thereby restricted the range of values and
possibly the association with MMP genetic variation. Although the submillimeter fibrous cap
thickness measurements were limited by our scan resolution, we observed moderate reliability
for these measurements as reported by Wasserman et al. (43), perhaps due to the reader's ability
to visually interpolate the cap boundaries with approximate accuracy. With regards to multiple
testing, the fact that statistically significant associations were observed for all three MMP2
SNPs (rs243864, rs243865, rs243866) and all cap measures provides evidence that these
associations are not due to chance alone. Despite these limitations, the strengths of the present
study include its being a well-characterized sample of a population-based cohort utilizing a
standardized MRI protocol with central reading and reliability data and a novel phenotype.
MMPs have established functions that might increase or decrease plaque growth and stability
through a variety of mechanisms (36). Previous studies of genetic variants in MMP gene
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promoter regions have revealed associations with atherosclerotic plaque progression and
stability (36). Although replication of the current study is warranted in other populations,
results from the current study show that variation within the promoter region of the MMP2
gene is associated with cap thickness and therefore may influence the role of MMP2 in plaque
vulnerability.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Descriptive Statistics of ARIC Carotid MRI Study Participants*
Characteristics African-American Women(N=230)
African-American Men
(N=159)
White Women
(N=640)
White Men
(N=672)
Age (years) 69.2 (0.4) 69.0 (0.5) 70.3 (0.3) 71.0 (0.3)
LDL Cholesterol (mg/dl) 127.1 (3.2) 119.1 (2.9) 118.8 (1.6) 105.5 (1.8)
HDL Cholesterol (mg/dl) 54.9 (1.2) 45.6 (1.0) 55.3 (0.8) 43.7 (0.5)
Systolic Blood Pressure (mmHg) 127.3 (1.6) 127.4 (2.1) 126.5 (0.9) 123.3 (0.9)
Diastolic Blood Pressure (mmHg) 66.9 (0.8) 71.4 (1.1) 65.8 (0.5) 67.2 (0.5)
BMI (kg/m2) 30.5 (0.4) 28.4 (0.4) 28.0 (0.3) 28.1 (0.2)
Current Smoker 8.2% 13.5% 7.5% 6.8%
Former Smoker 28.5% 42.6% 33.1% 58.6%
Hypertensive 79.2% 67.6% 61.8% 57.4%
Hypertensive medication use 78.2% 62.0% 62.2% 57.6%
Diabetes 31.1% 39.9% 17.7% 22.1%
Diabetes Medication use 19.6% 28.8% 10.8% 13.7%
Statin use 23.4% 26.4% 31.9% 41.0%
Data presented as mean (standard error of the mean) or percentages;
*
Carotid MRI participants defined as those with complete quality MRI scan data and not restricted to those with genotype data
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